{"schema_version":"1","generated_at":"2026-10-28T18:02:58.650Z","data_as_of":"2026-10-23","url":"https://www.findmykol.com/kol/sumithira-vasu","json_url":"https://www.findmykol.com/kol/sumithira-vasu/profile.json","record_kind":"full","profile_kind":"clinical","person":{"slug":"sumithira-vasu","name":"Sumithira Vasu","credential":"MD","title":"Professor","specialty":"Hematology","specialty_raw":"Hematology","therapeutic_area":"Leukemia","therapeutic_areas":["Leukemia"],"institution":"The Ohio State University","institution_url":"https://www.findmykol.com/institution/the-ohio-state-university","city":"Columbus","state":"OH","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"},"country":{"name":"United States","code":"US","status":"verified"}},"identifiers":{"npi":"1710159744","orcid":"0000-0002-8635-3880","openalex":"A5102862783"},"summary":"Sumithira Vasu is Professor at The Ohio State University. OpenAlex indexes 371 publications with 4,198 citations (h-index 33); ClinicalTrials.gov lists 10 registered studies with this person as an investigator.","overview":{"text":"Sumithira Vasu, M.D., is Professor at The Ohio State University. The public record shows 371 publications with 4,198 citations (h-index 33), centered on Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia Research, Renal Transplantation Outcomes and Treatments. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 5 companies, 3 NIH-funded awards (2017–2026).","bullets":["Most recent indexed publication: 2026 · Blood cancer discovery","Top research focus: Hematopoietic Stem Cell Transplantation","10 registered trials on ClinicalTrials.gov","Open Payments reporting from 5 companies"],"generated_at":"2026-10-28"},"focus":{"indications":[{"label":"Leukemia (AML/ALL/CML/CLL)","therapeutic_area":"Oncology","trials":8,"topics":1,"strength":25},{"label":"Leukemia, Myeloid, Acute","therapeutic_area":"Oncology","trials":6,"topics":0,"strength":18},{"label":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","therapeutic_area":"Oncology","trials":4,"topics":0,"strength":12},{"label":"MDS / MPN","therapeutic_area":"Oncology","trials":3,"topics":0,"strength":9},{"label":"Lymphoma","therapeutic_area":"Oncology","trials":3,"topics":0,"strength":9},{"label":"Lymphoma, Non-Hodgkin","therapeutic_area":"Oncology","trials":3,"topics":0,"strength":9},{"label":"Hodgkin Disease","therapeutic_area":"Oncology","trials":3,"topics":0,"strength":9},{"label":"Leukemia, Lymphocytic, Chronic, B-Cell","therapeutic_area":"Oncology","trials":2,"topics":0,"strength":6},{"label":"Leukemia, Lymphoid","therapeutic_area":"Oncology","trials":2,"topics":0,"strength":6},{"label":"Multiple Myeloma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Hematologic Neoplasms","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Autoimmune Diseases","therapeutic_area":"Rheumatology/Immunology","trials":1,"topics":0,"strength":3},{"label":"Immune System Diseases","therapeutic_area":"Rheumatology/Immunology","trials":1,"topics":0,"strength":3},{"label":"Anemia, Aplastic","therapeutic_area":"Hematology","trials":1,"topics":0,"strength":3},{"label":"Tic Disorders","therapeutic_area":"Neurology","trials":1,"topics":0,"strength":3},{"label":"Lymphoma, B-Cell","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Leukemia, Prolymphocytic","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Leukemia, Prolymphocytic, B-Cell","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Vitamin D Deficiency","therapeutic_area":"Endocrinology/Metabolic","trials":1,"topics":0,"strength":3},{"label":"Graft vs Host Disease","therapeutic_area":"Rheumatology/Immunology","trials":1,"topics":0,"strength":3},{"label":"Vitamin A Deficiency","therapeutic_area":"Endocrinology/Metabolic","trials":1,"topics":0,"strength":3},{"label":"Blast Crisis","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Neoplasm, Residual","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3}],"research_topics":["Hematopoietic Stem Cell Transplantation","Acute Myeloid Leukemia Research","Renal Transplantation Outcomes and Treatments","Transplantation: Methods and Outcomes","CAR-T cell therapy research"],"drugs_studied":{"total":3,"shown":3,"withheld":0,"rows":[{"name":"Amtagvi","generic":"Lifileucel","trials":0,"payments":1,"publications":0,"mentions":1},{"name":"K-NK002","trials":1,"payments":0,"publications":0,"mentions":1},{"name":"Ultomiris","generic":"Ravulizumab","trials":0,"payments":1,"publications":0,"mentions":1}]},"works_with":{"total":10,"shown":3,"withheld":7,"rows":[{"name":"National Marrow Donor Program","trials":0,"payments":9,"mentions":9},{"name":"Sumithira Vasu","trials":6,"payments":0,"mentions":6},{"name":"Novartis Pharmaceuticals Corporation","trials":0,"payments":3,"mentions":3}]}},"scholarship":{"works_count":371,"cited_by_count":4198,"h_index":33,"i10_index":81,"pubmed_count":6,"latest_activity_year":2026,"source":"works"},"trials":{"count":10,"shown":3,"withheld":7,"matched_by":"identity-adjudicated record","rows":[{"nct":"NCT07166419","title":"Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia","phase":"PHASE1","status":"SUSPENDED","role":"Investigator","sponsor":"Ohio State University Comprehensive Cancer Center","source_url":"https://clinicaltrials.gov/study/NCT07166419","trial_url":"https://www.findmykol.com/trial/NCT07166419"},{"nct":"NCT06450925","title":"Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.","phase":"PHASE2","status":"RECRUITING","role":"Investigator","sponsor":"Children's Hospital Medical Center, Cincinnati","source_url":"https://clinicaltrials.gov/study/NCT06450925","trial_url":"https://www.findmykol.com/trial/NCT06450925"},{"nct":"NCT05418088","title":"Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies","phase":"PHASE1","status":"RECRUITING","role":"Investigator","sponsor":"Sumithira Vasu","source_url":"https://clinicaltrials.gov/study/NCT05418088","trial_url":"https://www.findmykol.com/trial/NCT05418088"}],"source":"trials"},"payments":{"company_count":5,"program_years":{"first":2021,"last":2025},"rows_total":7,"shown":3,"withheld":4,"rows":[{"payer":"Novartis Pharmaceuticals Corporation","program_year":2025,"amount_usd":6427.26,"payment_count":3,"source_url":"https://openpaymentsdata.cms.gov/search?query=1710159744"},{"payer":"National Marrow Donor Program","program_year":2025,"amount_usd":1969.66,"payment_count":5,"source_url":"https://openpaymentsdata.cms.gov/search?query=1710159744"},{"payer":"National Marrow Donor Program","program_year":2024,"amount_usd":1201,"payment_count":3,"source_url":"https://openpaymentsdata.cms.gov/search?query=1710159744"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1710159744","source":"payments"},"prescribing":{"data_year":2024,"areas_total":1,"areas_shown":1,"areas":[{"area":"Cancer & immunology","share_pct":100,"classes_total":5,"classes":[{"class":"Kinase inhibitor","setting":"prescribed","share_pct":63.5,"drugs":[{"name":"Jakafi","share_pct":85.8},{"name":"Tasigna","share_pct":14.2}],"max_beneficiaries":null},{"class":"Nucleoside Metabolic Inhibitor","setting":"prescribed","share_pct":12.4,"drugs":[{"name":"Onureg","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2024,"office_pct":0,"facility_pct":100},"source":"medicare"},"funding":{"award_count":3,"fiscal_years":{"first":2017,"last":2026},"rows_total":19,"shown":3,"withheld":16,"rows":[{"project":"R01CA276374","title":"Trispecific CAR-T cells targeting CD19, CD20 and CD22 to treat B-cell malignancies","fiscal_year":2026,"amount_usd":609273,"organization":"OHIO STATE UNIVERSITY","source_url":"https://reporter.nih.gov/quickSearch/R01CA276374"},{"project":"UG1HL109322","title":"BMT Core- The Ohio State University blood and marrow transplant research consortium","fiscal_year":2026,"amount_usd":219365,"organization":"OHIO STATE UNIVERSITY","source_url":"https://reporter.nih.gov/quickSearch/UG1HL109322"},{"project":"R01CA276374","title":"Trispecific CAR-T cells targeting CD19, CD20 and CD22 to treat B-cell malignancies","fiscal_year":2025,"amount_usd":609273,"organization":"OHIO STATE UNIVERSITY","source_url":"https://reporter.nih.gov/quickSearch/R01CA276374"}],"source":"grants"},"congress":{"count":79,"years":{"first":2015,"last":2025},"societies":["AACR","ASCO","ASH"],"shown":3,"withheld":76,"rows":[{"title":"Outcomes in patients (pts) younger than 50 years old (yo) with treatment-naïve blastic plasmacytoid dendritic cell neoplasm (BPDCN) treated with tagraxofusp (TAG): Subanalysis of a phase 1/2 trial.","society":"ASCO","meeting":"ASCO Annual Meeting","year":2025,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1200/jco.2025.43.16_suppl.6518","source_url":"https://doi.org/10.1200/jco.2025.43.16_suppl.6518","status":"verified"},{"title":"Outcomes of older matched sibling donors compared to younger matched unrelated donors in allogeneic hematopoietic cell transplantation for AML in first complete remission.","society":"ASCO","meeting":"ASCO Annual Meeting","year":2025,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1200/jco.2025.43.16_suppl.e18558","source_url":"https://doi.org/10.1200/jco.2025.43.16_suppl.e18558","status":"verified"},{"title":"Subgroup analysis by fitness criteria of patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN) treated with first-line (1L) tagraxofusp (TAG).","society":"ASCO","meeting":"ASCO Annual Meeting","year":2025,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1200/jco.2025.43.16_suppl.6531","source_url":"https://doi.org/10.1200/jco.2025.43.16_suppl.6531","status":"verified"}],"source":"congress"},"publications":{"total":6,"shown":5,"withheld":1,"matched_by":"ORCID record, linked to PubMed","recent":[{"title":"Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22.","year":2026,"journal":"Blood cancer discovery","types":["Journal Article","Clinical Trial, Phase I"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42446920/","status":"verified"},{"title":"TA-TMA and GVHD are distinct consequences of endothelial injury: a MIDAS consortium study.","year":2026,"journal":"Blood advances","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42234937/","status":"verified"},{"title":"Biallelic germline MBD4 mutations predispose to colorectal polyposis, hypermutated AML, and schwannomas.","year":2026,"journal":"Familial cancer","types":["Journal Article","Case Reports"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42101541/","status":"verified"},{"title":"Successful engraftment in myeloablative transplant with cadaveric bone marrow after sudden unavailability of living donor.","year":2026,"journal":"Blood advances","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/41259738/","status":"verified"},{"title":"High incidence of severe TA-TMA increases mortality in adult allogeneic transplant recipients: a prospective MIDAS Consortium study.","year":2025,"journal":"Blood","types":["Journal Article","Multicenter Study"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/40300075/","status":"verified"}],"most_cited":{"total":371,"shown":5,"withheld":366,"rows":[{"title":"Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm","year":2019,"cited_by_count":437,"type":"article","source_url":"https://doi.org/10.1056/nejmoa1815105"},{"title":"Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology","year":2017,"cited_by_count":157,"type":"article","source_url":"https://doi.org/10.6004/jnccn.2017.0175"},{"title":"Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research","year":2022,"cited_by_count":152,"type":"article","source_url":"https://doi.org/10.1016/j.jtct.2022.11.015"},{"title":"Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome","year":2021,"cited_by_count":150,"type":"article","source_url":"https://doi.org/10.1200/jco.20.03380"},{"title":"Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors","year":2015,"cited_by_count":144,"type":"article","source_url":"https://doi.org/10.1016/j.bbmt.2015.10.005"}]},"source":"publications"},"network":{"coauthors_total":40,"shown":3,"withheld":37,"coauthors":[{"name":"Sarah Allison Wall","coauthored_works":99},{"name":"Sam L. Penza","coauthored_works":97},{"name":"Samantha Mary Jaglowski","coauthored_works":92}],"source":"works"},"presence":{"owned_accounts":{"total":1,"shown":1,"rows":[{"platform":"doximity","url":"https://www.doximity.com/pub/sumithira-vasu-md","status":"verified"}]},"mentions":{"total":1,"shown":1,"rows":[{"url":"https://healthtree.org/aml/community/directory/oh/the-ohio-state-university-comprehensive-cancer-center-columbus-oh/sumithira-vasu","platform":"other","status":"verified"}]},"verified_means":"confirmed in more than one place; provisional means found and still being confirmed"},"recognition":{"education":{"total":1,"shown":1,"rows":[{"value":"MD","source_url":"https://www.aamds.org/node/2848","status":"verified","collected_at":"2026-10-28"}]},"secondary_affiliations":{"total":1,"shown":1,"rows":[{"value":"Center for Regenerative Medicine and Cell-Based Therapies (research unit)","source_url":"https://ohiostate.elsevierpure.com/en/persons/sumithira-vasu/","status":"verified","collected_at":"2026-10-28"}]}},"similar":[{"name":"Jennifer Woyach","slug":"jennifer-woyach","institution":"The Ohio State University","specialty":"Hematology","url":"https://www.findmykol.com/kol/jennifer-woyach","json_url":"https://www.findmykol.com/kol/jennifer-woyach/profile.json"},{"name":"Yuchi Han","slug":"yuchi-han","institution":"The Ohio State University","specialty":"Cardiovascular Disease","url":"https://www.findmykol.com/kol/yuchi-han","json_url":"https://www.findmykol.com/kol/yuchi-han/profile.json"},{"name":"Uma Borate","slug":"uma-borate","institution":"The Ohio State University","specialty":"Hematology","url":"https://www.findmykol.com/kol/uma-borate","json_url":"https://www.findmykol.com/kol/uma-borate/profile.json"},{"name":"Sooyoung Kim","slug":"sooyoung-kim","institution":"The Ohio State University","url":"https://www.findmykol.com/kol/sooyoung-kim","json_url":"https://www.findmykol.com/kol/sooyoung-kim/profile.json"},{"name":"Hagop Kantarjian","slug":"hagop-kantarjian","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/hagop-kantarjian","json_url":"https://www.findmykol.com/kol/hagop-kantarjian/profile.json"},{"name":"Jorge Cortes","slug":"jorge-cortes","institution":"University of Alabama at Birmingham (UAB)","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/jorge-cortes","json_url":"https://www.findmykol.com/kol/jorge-cortes/profile.json"},{"name":"Ayalew Tefferi","slug":"ayalew-tefferi","institution":"Mayo Clinic","specialty":"Hematology","url":"https://www.findmykol.com/kol/ayalew-tefferi","json_url":"https://www.findmykol.com/kol/ayalew-tefferi/profile.json"},{"name":"Charles Sawyers","slug":"charles-sawyers","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/charles-sawyers","json_url":"https://www.findmykol.com/kol/charles-sawyers/profile.json"}],"coverage":{"note":"An identity-adjudicated profile: every section above was checked. Where a section states a count of zero, the public record was searched and nothing was found."},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":7,"payments":4,"funding":16,"congress":76,"publications":1,"network":37}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts","collected_at":"2026-10-28"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies","collected_at":"2026-10-28"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 to 2025","collected_at":"2026-10-28"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year","collected_at":"2026-10-28"},"congress":{"name":"OpenAlex","url":"https://openalex.org","provides":"DOI-verified congress abstracts across AACR, ASCO, ASH, ASTRO, ESMO","disclaimer":"Congress abstracts are published as DOI-bearing journal supplements and attributed via the same ORCID-disambiguated authorship as publications.","collected_at":"2026-10-28"},"publications":{"name":"PubMed (NLM)","url":"https://pubmed.ncbi.nlm.nih.gov","provides":"Peer-reviewed publications, linked to the PubMed record","collected_at":"2026-10-28"}},"methodology_url":"https://www.findmykol.com/about#methodology"}